DR. HELIX PEPTIDES
PRECISION · QUALITY · RESULTS

Retatrutide

Triple Receptor Agonist · GIP / GLP-1 / Glucagon

OVERVIEW

Retatrutide (LY3437943) is a next-generation triple receptor agonist simultaneously targeting GIP, GLP-1, and glucagon receptors. Clinical trials demonstrate weight loss outcomes surpassing all existing GLP-1 and dual agonist therapies, positioning it as the most potent metabolic peptide currently available. Its simultaneous triple-receptor activation provides a comprehensive and unrivaled metabolic reset across multiple organ systems.

SPECIFICATIONS

Size	20mg per vial
Reconstitution	Add 3ml BAC Water → 6,667mcg/ml
Route	Subcutaneous (SubQ) injection
Frequency	Once weekly — titrate very slowly
Storage	Refrigerate 2–8°C; protect from light

CLINICAL APPLICATIONS

■ Highest weight reduction — any peptide	■ Type 2 diabetes & insulin sensitivity
■ NAFLD / NASH hepatic fat reduction	■ Cardiovascular risk reduction
■ Lean muscle preservation	■ Advanced treatment-resistant obesity

MECHANISM OF ACTION

GLP-1R activation enhances insulin secretion and reduces appetite centrally. GIPR activation synergizes for greater insulin response and adipose metabolism. Glucagon receptor activation increases energy expenditure and hepatic fat oxidation. The additive triple-receptor effect consistently and substantially exceeds dual or single agonist therapies across all metabolic outcomes measured.

RECONSTITUTION & DOSING GUIDE · SubQ Injection · U-100 Insulin Syringe

3ml BAC Water + 20mg vial = 6,667mcg/ml · U-100 syringe: 15 units ≈ 1mg · Titrate slowly — do not skip steps

PHASE	DOSE	SYRINGE UNITS (U-100)	FREQUENCY
Starting (Wk 1–4)	2mg	30 units	Once weekly
Titration (Wk 4–8)	4mg	60 units	Once weekly
Titration (Wk 8–12)	6mg	90 units	Once weekly
Titration (Wk 12+)	8mg	120 units	Once weekly
High Dose	10mg	150 units	Once weekly
Max Dose	12mg	180 units	Once weekly